Cargando…

P1574: EFFICACY AND SAFETY OF TIXAGEVIMAB AND CILGAVIMAB (EVUSHELD) IN PATIENTS WITH HEMATOLOGICAL MALIGNANCIES

Detalles Bibliográficos
Autores principales:	Aleshina (Gavrilina), Olga, Zhabrailova, Amina, Troistskaya, Vera
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Posters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10430326/ http://dx.doi.org/10.1097/01.HS9.0000973172.68761.f9

Ejemplares similares

Real-World Effectiveness of Tixagevimab and Cilgavimab (Evusheld) in Patients With Hematological Malignancies
por: Ocon, Anthony J., et al.
Publicado: (2022)

Real world effectiveness of tixagevimab/cilgavimab (Evusheld) in the Omicron era
por: Chen, Benjamin, et al.
Publicado: (2023)

P57 PRE-EXPOSURE PROPHYLAXIS FOR COVID-19 WITH TIXAGEVIMAB/CILGAVIMAB (EVUSHELD) IN PATIENTS WITH MULTIPLE MYELOMA
por: Ntanasis-Stathopoulos, I., et al.
Publicado: (2023)

Tixagevimab and Cilgavimab (Evusheld – AstraZeneca) efficacy in preventing COVID infection in immunocompromised patients
por: Miot, Christelle, et al.
Publicado: (2023)

Tixagevimab and Cilgavimab (Evusheld) in Rituximab-treated Antineutrophil Cytoplasmic Antibody Vasculitis Patients
por: Aqeel, Faten, et al.
Publicado: (2022)

Safety and efficacy of pre-exposure prophylaxis with tixagevimab/cilgavimab (Evusheld) in patients with glomerular diseases who received rituximab
por: Sciascia, Savino, et al.
Publicado: (2023)

‘Real-World’ Impact of Tixagevimab/Cilgavimab (Evusheld) on COVID-19 Outcomes in Patients Undergoing Cellular Therapies
por: Sannareddy, Aishwarya, et al.
Publicado: (2023)

Pre-exposure prophylaxis with tixagevimab and cilgavimab (Evusheld) for COVID-19 among 1112 severely immunocompromised patients
por: Nguyen, Yann, et al.
Publicado: (2022)

P1574: ANTINEOPLASTIC THERAPY FOR HEMATOLOGIC MALIGNANCIES DURING COVID-19
por: Chudnova, T., et al.
Publicado: (2022)

A Critical Analysis of the Use of Cilgavimab plus Tixagevimab Monoclonal Antibody Cocktail (Evusheld™) for COVID-19 Prophylaxis and Treatment
por: Focosi, Daniele, et al.
Publicado: (2022)

Tixagevimab and Cilgavimab (Evusheld™) Prophylaxis Prevents Breakthrough COVID-19 Infections in Immunosuppressed Population: 6-Month Prospective Study
por: Jakimovski, Dejan, et al.
Publicado: (2023)

Tixagevimab and Cilgavimab (Evusheld) Boosts Antibody Levels to SARS-Cov-2 in Patients with Multiple Sclerosis on B-Cell Depleters
por: Conte, William L., et al.
Publicado: (2023)

(701) Use of Tixagevimab and Cilgavimab (Evusheld) and Subsequent Outcomes of SARS-CoV-2 Infections in Lung Transplant Recipients
por: Grillini, A., et al.
Publicado: (2023)

Tixagevimab and Cilgavimab (Evusheld) boosts antibody levels to SARS-CoV-2 in patients with multiple sclerosis on b-cell depleters
por: Conte, William L., et al.
Publicado: (2022)

Tixagevimab + Cilgavimab: First Approval
por: Keam, Susan J.
Publicado: (2022)

The Prevention of COVID-19 in High-Risk Patients Using Tixagevimab–Cilgavimab (Evusheld): Real-World Experience at a Large Academic Center
por: Al-Obaidi, Mohanad M., et al.
Publicado: (2023)

Tixagevimab and Cilgavimab (Evusheld) as Pre-exposure Prophylaxis for COVID-19 in Patients With Inflammatory Bowel Disease: A Propensity Matched Cohort Study
por: Desai, Aakash, et al.
Publicado: (2023)

P1513: REDUCTION OF THE PROPHYLACTIC EFFECT OF TIXAGEVIMAB-CILGAVIMAB IN THE OMICRON ERA IN PATIENTS WITH HEMATOLOGICAL MALIGNANCIES AND WITHOUT ANTIBODY RESPONSE FOLLOWING SARS-COV-2 VACCINATION.
por: Callegari, Chiara, et al.
Publicado: (2023)

Tixagevimab and cilgavimab for COVID-19 prophylaxis
Publicado: (2022)

Tixagevimab/Cilgavimab as pre-exposure prophylaxis against SARS-CoV-2 in patients with hematological malignancies
por: Angotzi, Francesco, et al.
Publicado: (2023)

Tixagevimab/ Cilgavimab Outcomes Among Patients with Immunodeficiency
por: Sullivan, Juliana
Publicado: (2023)

P1558: PROPHYLAXIS WITH TIXAGEVIMAB-CILGAVIMAB IN SINGLE-CENTER EXPERIENCE CAN REDUCE SEVERE COMPLICATIONS RELATED TO SARS-COV-2 INFECTION IN HEMATOLOGICAL PATIENTS
por: Duminuco, Andrea, et al.
Publicado: (2023)

Activity of AZD7442 (tixagevimab-cilgavimab) against Omicron SARS-CoV-2 in patients with hematologic malignancies
por: Stuver, Robert, et al.
Publicado: (2022)

PB2586: PASSIVE PREEXPOSURE IMMUNIZATION BY TIXAGEVIMAB/CILGAVIMAB IN COVID 19 INFECTED HEMATOLOGICAL MALIGNANCY OF EPICOVIDHEA SURVEY
por: Buquicchio, Caterina, et al.
Publicado: (2023)

SARS-CoV-2 infection in high-risk children following tixagevimab–cilgavimab (Evusheld) pre-exposure prophylaxis: a single-center observational study
por: Hijano, Diego R., et al.
Publicado: (2023)

Efficacy of tixagevimab-cilgavimab in preventing SARS-CoV-2 for patients with B-cell malignancies
por: Davis, James A., et al.
Publicado: (2023)

Passive pre-exposure immunization by tixagevimab/cilgavimab in patients with hematological malignancy and COVID-19: matched-paired analysis in the EPICOVIDEHA registry
por: Marchesi, Francesco, et al.
Publicado: (2023)

Evolution of Humoral and Cellular Immunity Post–Breakthrough Coronavirus Disease 2019 in Vaccinated Patients With Hematologic Malignancy Receiving Tixagevimab-Cilgavimab
por: Hall, Victoria G, et al.
Publicado: (2023)

Efficacy of Preexposure Prophylaxis with Monoclonal-Antibody AZD7442 (tixagevimab-cilgavimab) Against Sars-Cov-2 Variants in Patients with CLL
por: Benjamini, Ohad, et al.
Publicado: (2022)

Intramuscular AZD7442 (Tixagevimab–Cilgavimab) for Prevention of Covid-19
por: Levin, Myron J., et al.
Publicado: (2022)

Cilgavimab/Tixagevimab as alternative therapeutic approach for BA.2 infections
por: Dichtl, Stefanie, et al.
Publicado: (2022)

A case of prolonged COVID‐19 treated with tixagevimab/cilgavimab
por: Shimizu, Takahiro, et al.
Publicado: (2023)

Safety and immunogenicity of cilgavimab-tixagevimab for COVID-19 pre-exposure prophylaxis in immunocompromised patients
por: Fernández-Prada, María, et al.
Publicado: (2023)

A Model-Based Cost-Effectiveness Analysis of Long-Acting Monoclonal Antibody (Tixagevimab and Cilgavimab: Evusheld) Preventive Treatment for High-Risk Populations Against SARS-CoV-2 in Korea
por: Jo, Youngji, et al.
Publicado: (2023)

Loss of Neutralizing Activity of Tixagevimab/Cilgavimab (Evusheld™) Against Omicron BN.1, a Dominant Circulating Strain Following BA.5 During the Seventh Domestic Outbreak in Korea in Early 2023
por: Yang, Jinyoung, et al.
Publicado: (2023)

Tixagevimab/Cilgavimab Pre-exposure Prophylaxis in Patients With Lymphoproliferative Disorders on BTKi
por: Zamprogna, Giulia, et al.
Publicado: (2023)

Efficacy and Safety of Tixagevimab/Cilgavimab to Prevent COVID-19 (Pre-Exposure Prophylaxis): A Systematic Review and Meta-Analysis
por: Alhumaid, Saad, et al.
Publicado: (2022)

Cardiac and vascular serious adverse events following tixagevimab–cilgavimab – Author's reply
por: Maselkar, Sheetal, et al.
Publicado: (2023)

Differential serum neutralisation of omicron sublineages in patients receiving prophylaxis with tixagevimab–cilgavimab
por: Solera, Javier T, et al.
Publicado: (2023)

1339. Effects of Tixagevimab-Cilgavimab in Clinical Practice is Consistent with Preliminary Neutralization Studies
por: Dluzynski, Daniela, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_7tp0q32k2bn1vkan427qvtics7